Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -65.16% is 11% above its 5-year average of -73.53%, near the high end of its 5-year range (-239.42%–0.00%).
18.62% above its 12-month average of -80.06%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.44%.
RETURN ON ASSETS (ROA)
-65.16%
RETURN ON ASSETS (ROA) AVG TTM
-80.06%
RETURN ON ASSETS (ROA) AVG 3Y
-104.26%
RETURN ON ASSETS (ROA) AVG 5Y
-73.53%
RETURN ON ASSETS (ROA) AVG 10Y
-1471.77%
RETURN ON ASSETS (ROA) AVG 15Y
-290.41%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.62%
CURRENT VS 3Y AVG
+37.50%
CURRENT VS 5Y AVG
+11.38%
CURRENT VS 10Y AVG
+95.57%
CURRENT VS 15Y AVG
+77.56%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-142.23%
vs the sector median at left
Bone Biologics Corporation
Market Cap
$897948.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$893920.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$877747.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$815044.00
Return on Assets (ROA)
-63.04%
TTM Avg
-106.06%
3Y Avg
-121.33%
5Y Avg
-96.21%
Market Cap
$1.01M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$693655.00
Return on Assets (ROA)
2.60%
TTM Avg
-212.84%
3Y Avg
-24543.27%
5Y Avg
-19977.79%
Market Cap
$1.09M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.13M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
Market Cap
$1.16M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bone Biologics Corporation (BBLG) | $897948.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| Decoy Therapeutics Inc. (DCOY)vs › | $877747.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $815044.00 | -63.04% | -106.06% | -121.33% | -96.21% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -81.60% | -1375.39% | -681.84% | -547.21% |
| CDT Equity Inc. (CDT)vs › | $693655.00 | 2.60% | -212.84% | -24543.27% | -19977.79% |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | -44.32% | -57.72% | -286.30% | -215.47% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -8.84% | -4.56% | 8.88% | 8.88% |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | -64.99% | -31.34% | -98.36% | -79.15% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.15M | -247.39% | -97.35% | -1378.80% | -1078.71% |
ROA
-65.2%
ROE
-73.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -53.64% |
| 2024-12-31 | -106.49% |
| 2023-12-31 | -239.42% |
| 2022-12-31 | -17.48% |
| 2021-12-31 | -24.13% |
| 2020-12-31 | 0.00% |
| 2019-12-31 | -11109.78% |
| 2018-12-31 | -425.67% |
| 2017-12-31 | -886.31% |
| 2016-12-31 | -2659.48% |
| 2015-12-31 | -667.10% |
| 2014-12-31 | -115.77% |
| 2013-10-31 | -1239.33% |
| 2012-10-31 | 0.00% |
| 2011-10-31 | 0.00% |
| 2010-10-31 | 0.00% |
| 2009-10-31 | 0.00% |
| 2008-10-31 | 0.00% |
